APPLICATION
ANDA077534
TYPE
ANDA
ORIGINAL APPROVAL
2006-10-03
LATEST ACTION
2024-09-18
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription
Products
CITALOPRAM HYDROBROMIDEPrescription
CITALOPRAM HYDROBROMIDE EQ 40MG BASE · TABLET · ORAL
CITALOPRAM HYDROBROMIDEPrescription
CITALOPRAM HYDROBROMIDE EQ 10MG BASE · TABLET · ORAL
CITALOPRAM HYDROBROMIDEPrescription
CITALOPRAM HYDROBROMIDE EQ 20MG BASE · TABLET · ORAL
Approval history
2024-09-18Labeling · Supplement 25 · standardAP
2024-04-16Labeling · Supplement 24 · standardAP
2022-11-21Labeling · Supplement 14 · standardAP
2022-11-21Labeling · Supplement 20 · standardAP
2022-11-21Labeling · Supplement 19 · standardAP
2022-11-21Labeling · Supplement 17 · standardAP
2015-03-09Labeling · Supplement 9 · standardAP
2015-03-09Labeling · Supplement 10 · standardAP
2013-04-26Labeling · Supplement 6 · standardAP
2012-04-25Labeling · Supplement 4AP
2009-08-21Labeling · Supplement 2AP
2007-06-28Labeling · Supplement 1AP
2006-10-03OriginalAP
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.